No, Restarting Vyvanse After a One-Year Gap Requires Full Clinical Re-evaluation
It is not appropriate to restart Vyvanse in a 14-year-old patient after a one-year discontinuation without conducting a comprehensive clinical re-evaluation. This recommendation is based on both FDA safety requirements and AAP clinical practice guidelines that mandate specific assessments before initiating or reinitiating stimulant therapy 1, 2.
Why Re-evaluation is Mandatory
Cardiac Safety Assessment is Non-Negotiable
Before restarting Vyvanse, you must obtain:
Personal cardiac history screening for:
- Specific cardiac symptoms (chest pain, syncope, palpitations, exercise intolerance)
- Any new cardiac diagnoses in the past year
Family cardiac history screening for:
- Sudden death (especially in young relatives)
- Wolff-Parkinson-White syndrome
- Hypertrophic cardiomyopathy
- Long QT syndrome
- Cardiovascular symptoms in first-degree relatives
If any risk factors are present, obtain an ECG before restarting medication 1, 2. The FDA explicitly warns against use in patients with structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, or coronary artery disease 2.
Growth Monitoring Requirements
After a one-year gap, you must reassess:
- Current height and weight with plotting on growth curves
- Growth trajectory over the past year off medication
- Whether the patient experienced catch-up growth during the medication-free period
This is critical because stimulants cause persistent decreases in growth velocity of 1-2 cm from predicted adult height, with effects most pronounced at higher, consistently administered doses 1. The year off medication may have allowed for some growth recovery that needs documentation.
Psychiatric and Symptom Re-assessment
A year is substantial in adolescent development. You must:
Screen for new psychiatric conditions that emerged during the medication-free year:
- Manic symptoms or bipolar disorder risk factors
- Psychotic symptoms
- Suicidal ideation
- Tics or Tourette's syndrome (assess family history and clinical presentation)
Reassess current ADHD symptom severity to confirm:
- The diagnosis remains valid
- Symptoms are causing functional impairment
- Medication is still clinically indicated
The FDA requires screening for risk factors for developing manic episodes before initiating treatment 2. New psychiatric symptoms may have emerged during adolescence that would contraindicate or require modified treatment.
Baseline Vital Signs
Establish new baseline measurements:
- Blood pressure (both systolic and diastolic)
- Heart rate
- Weight
Stimulants increase heart rate by 1-2 beats per minute and blood pressure by 1-4 mm Hg on average, but 5-15% of individuals experience more substantial increases requiring monitoring 1.
Clinical Pitfalls to Avoid
Do not assume the previous dose is still appropriate. After a year off medication:
- The patient's weight has likely changed significantly (adolescent growth)
- Tolerance has reset
- Metabolic factors may have changed
Do not overlook substance use screening. At age 14, assess for any substance experimentation during the medication-free year, as this affects treatment decisions and monitoring intensity.
Do not skip the discussion about why medication was stopped. Understanding the reason for the one-year gap (side effects, lack of efficacy, family preference, access issues) informs whether restarting is appropriate and what modifications might be needed.
The Bottom Line
The combination of cardiac safety requirements, growth monitoring needs, psychiatric screening mandates, and the significant developmental changes that occur during a year in adolescence make re-evaluation essential—not optional—before restarting Vyvanse 1, 2. Treating this as a new medication initiation rather than a simple restart is the safest approach and aligns with both FDA labeling requirements and AAP guidelines.